Sugi Predict

Sugi Predict / Compounds / SCHEMBL2209386

SCHEMBL2209386

SCHEMBL2209386

O=C(OCc1ccccc1)C1CC(F)(F)C1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 3/20 0.50
▸ SLC6A2 P23975 1/20 0.50
▸ SLC6A3 Q01959 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ FABP7 O15540 1/20 0.48
▸ FABP5 Q01469 1/20 0.48
▸ ALDH1A1 P00352 5/20 0.47
▸ LMNA P02545 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ TSHR P16473 1/20 0.45
▸ GAA P10253 1/20 0.44
▸ BACE1 P56817 1/20 0.44
▸ CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15106390 0.88 FABP7 (0.43) TDP1SLC6A2SLC6A3KMT2AFABP7
SCHEMBL15116655 0.88 ALDH1A1 (0.46) TDP1SLC6A2SLC6A3KMT2AFABP7
SCHEMBL3617827 0.88 SLC6A2 (0.45) TDP1SLC6A2SLC6A3KMT2AFABP7
SCHEMBL15457715 0.88 SLC6A2 (0.45) TDP1SLC6A2SLC6A3KMT2AFABP7
SCHEMBL15105956 0.88 ALDH1A1 (0.46) TDP1SLC6A2SLC6A3KMT2AFABP7
SCHEMBL15289517 0.88 ALDH1A1 (0.49) TDP1SLC6A2SLC6A3KMT2AFABP7
SCHEMBL15270499 0.88 ALDH1A1 (0.49) TDP1SLC6A2SLC6A3KMT2AFABP7
SCHEMBL21057311 0.87 TSHR (0.44) TDP1SLC6A2SLC6A3KMT2AFABP7
SCHEMBL21057322 0.87 TSHR (0.44) TDP1SLC6A2SLC6A3KMT2AFABP7
SCHEMBL19916998 0.87 TSHR (0.44) TDP1SLC6A2SLC6A3KMT2AFABP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3985001-B1 PHARMACEUTICAL COMPOSITION FOR USE IN TREATING A CANCER SERVIER LAB (FR) 2026-04-29 — — EP disclosed
EP-4634159-A1 SULFOXIMINES AS INHIBITORS OF NAV1.8 Grünenthal GmbH (DE) 2025-10-22 — — EP disclosed
US-20240252473-A1 Sulfoximines as inhibitors of NaV1.8 GRUENENTHAL GMBH (DE) 2024-08-01 — — US disclosed
WO-2024126648-A1 SULFOXIMINES AS INHIBITORS OF NaV1.8 Grünenthal GmbH (DE) 2024-06-20 — — WO disclosed
WO-2024126648-A1 SULFOXIMINES AS INHIBITORS OF NaV1.8 Grünenthal GmbH (DE) 2024-06-20 — — WO disclosed
US-11976083-B2 Inhibitors of peptidylarginine deiminases GILEAD SCIENCES, INC. (US) 2024-05-07 — — US disclosed
CN-115551862-B Macrocyclic inhibitors of peptidyl arginine deiminase 吉利德科学公司 2024-04-12 — — CN disclosed
US-20240059733-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC (US) 2024-02-22 — — US disclosed
EP-3743430-B1 AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-08-02 — — EP disclosed
US-11667673-B2 Therapeutically active compounds and their methods of use SERVIER PHARMACEUTICALS LLC (US) 2023-06-06 — — US disclosed
US-7981910-B2 Triazole derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase-1 MERCK SHARP & DOHME CORP. (US) 2011-07-19 — — US disclosed
US-7691887-B2 Triazole derivatives which are SMO antagonists MERCK SHARP & DOHME CORP. (US) 2010-04-06 — — US disclosed
US-7691887-B2 Triazole derivatives which are SMO antagonists MERCK SHARP & DOHME CORP. (US) 2010-04-06 — — US disclosed
US-20090258913-A1 Triazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 MERCK SHARP & DOHME LLC 2009-10-15 — — US disclosed
US-20090258913-A1 Triazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 MERCK SHARP & DOHME LLC 2009-10-15 — — US disclosed
EP-1940393-A4 TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 MERCK & CO INC (US) 2008-12-17 — — EP disclosed
US-20080262051-A1 Triazole derivatives which are SMO antagonists MERCK SHARP & DOHME LLC 2008-10-23 — — US disclosed
US-20080262051-A1 Triazole derivatives which are SMO antagonists MERCK SHARP & DOHME LLC 2008-10-23 — — US disclosed
EP-1940393-A2 TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 Merck & Co., Inc. (US) 2008-07-09 — — EP disclosed
WO-2007047625-A2 TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 MERCK & CO., INC. (US) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258913-A1 Triazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 HSD11B1, HSD17B1, HSD3B1 TDP1 691/4885SLC6A2 3150/4885SLC6A3 2537/4885
US-20080262051-A1 Triazole derivatives which are SMO antagonists SMO, GLI1, ROR1 TDP1 4378/4885SLC6A2 3732/4885SLC6A3 2293/4885
US-11976083-B2 Inhibitors of peptidylarginine deiminases PADI4, PADI2, PADI1 TDP1 199/4885SLC6A2 3962/4885SLC6A3 3249/4885
US-20240059733-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE IDH1, IDH3B, IDH3A TDP1 301/4885SLC6A2 3555/4885SLC6A3 3734/4885
US-11667673-B2 Therapeutically active compounds and their methods of use IDH1, IDH3B, IDH3A TDP1 301/4885SLC6A2 3555/4885SLC6A3 3734/4885
US-20240252473-A1 Sulfoximines as inhibitors of NaV1.8 SCN8A, SCN10A, SCN7A TDP1 2966/4885SLC6A2 309/4885SLC6A3 584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.